Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study

Ali T. Taher; Zeynep Karakas; Elena Cassinerio; Noppadol Siritanaratkul; Antonis Kattamis; Aurelio Maggio; Stefano Rivella; Norbert Hollaender; Bruyere Mahuzier; Brian Gadbaw; Yesim Aydinok

doi:10.1182/blood-2017-06-790121

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study

Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyere Mahuzier, Brian Gadbaw, Yesim Aydinok

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	263-265
Number of pages	3
Journal	Blood
Volume	131
Issue number	2
DOIs	https://doi.org/10.1182/blood-2017-06-790121
Publication status	Published - Jan 11 2018

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2017-06-790121

Cite this

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia : Results from a phase 2a study. / Taher, Ali T.; Karakas, Zeynep; Cassinerio, Elena; Siritanaratkul, Noppadol; Kattamis, Antonis; Maggio, Aurelio; Rivella, Stefano; Hollaender, Norbert; Mahuzier, Bruyere; Gadbaw, Brian; Aydinok, Yesim.

In: Blood, Vol. 131, No. 2, 11.01.2018, p. 263-265.

Research output: Contribution to journal › Letter › peer-review

Taher, Ali T. ; Karakas, Zeynep ; Cassinerio, Elena ; Siritanaratkul, Noppadol ; Kattamis, Antonis ; Maggio, Aurelio ; Rivella, Stefano ; Hollaender, Norbert ; Mahuzier, Bruyere ; Gadbaw, Brian ; Aydinok, Yesim. / Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia : Results from a phase 2a study. In: Blood. 2018 ; Vol. 131, No. 2. pp. 263-265.

@article{771fdb74ce644be08d9a12252f34dbeb,

title = "Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study",

author = "Taher, {Ali T.} and Zeynep Karakas and Elena Cassinerio and Noppadol Siritanaratkul and Antonis Kattamis and Aurelio Maggio and Stefano Rivella and Norbert Hollaender and Bruyere Mahuzier and Brian Gadbaw and Yesim Aydinok",

year = "2018",

month = jan,

day = "11",

doi = "10.1182/blood-2017-06-790121",

language = "English",

volume = "131",

pages = "263--265",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "2",

}

TY - JOUR

T1 - Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia

T2 - Results from a phase 2a study

AU - Taher, Ali T.

AU - Karakas, Zeynep

AU - Cassinerio, Elena

AU - Siritanaratkul, Noppadol

AU - Kattamis, Antonis

AU - Maggio, Aurelio

AU - Rivella, Stefano

AU - Hollaender, Norbert

AU - Mahuzier, Bruyere

AU - Gadbaw, Brian

AU - Aydinok, Yesim

PY - 2018/1/11

Y1 - 2018/1/11

UR - http://www.scopus.com/inward/record.url?scp=85040441699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040441699&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-06-790121

DO - 10.1182/blood-2017-06-790121

M3 - Letter

AN - SCOPUS:85040441699

VL - 131

SP - 263

EP - 265

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this